Mostafa Kamal Arefin1*, Md. Mosheur Rahman Chowdhury2, Abdullah Al Ferdoush3, Ibrahim Kishko4
1ENT specialist & Hybrid ENT surgeon, Consultant, Popular Medical College Hospital, Bangladesh
2Junior Consultant (Anaesthesia), Kurmitola General Hospital, Dhaka, Bangladesh
3Resident (ENT), National Institute of ENT, Dhaka, Bangladesh
4Dhaka Medical College & Hospital, Dhaka, Bangladesh
*Corresponding Author: Mostafa Kamal Arefin, ENT specialist & Hybrid ENT Surgeon, Consultant, Popular Medical College Hospital, Tel: +8801671748866; Email: [email protected]
Citation: Arefin MK, et al. (2026). A Combined Anatomical Scoring System for Upper-Airway Obstruction in OSA (ACUOS). Mathews J Otolaryngol. 5(1):14.
Copyright: Arefin MK, et al. © (2026).
ABSTRACT
Introduction: Obstructive sleep apnoea (OSA) arises from the collapse of the upper-airway during sleep and is influenced by multiple anatomical factors, including tonsillar hypertrophy, septal deviation, turbinate enlargement, tongue-base crowding, and elevated body mass index (BMI). Current clinical staging systems (e.g., Friedman) emphasize oropharyngeal compartments but often overlook nasal anatomical burden. We propose a unified anatomical scoring framework, Arefin’s Combined Upper-Airway Obstruction Score (ACUOS), which integrates nasal, palatal, and tongue-related contributors in a numeric system to guide treatment decisions in OSA.
Methods: Five anatomical contributors were selected based on their documented association with OSA severity and surgical outcomes. Each was assigned a 0–3 or 0–4 point range, totaling 0–16, with an optional adenoid modifier for pediatric cases. ACUOS staging (A–D) suggests first-line medical, surgical, or CPAP therapy.
Results: For example, a patient with tonsil grade 3 (3 points), septal obstruction grade 2 (2), inferior turbinate hypertrophy grade 2 (2), Mallampati II (1), and BMI 31 (2) scores 10 = Stage C → multilevel surgery or CPAP. ACUOS enables OPD-based anatomical guidance for OSA treatment. Conclusion: ACUOS provides a practical, bedside scoring approach to evaluate anatomical burden in OSA and assist ENT surgeons in surgical counseling and decision-making. Validation studies are required.
Keywords: Obstructive Sleep Apnoea, Airway Anatomy, Nasal Obstruction, Septal Deviation, Turbinate Hypertrophy
INTRODUCTION
Obstructive sleep apnoea (OSA) is characterized by repeated upperairway collapse during sleep, leading to sleep fragmentation and increased cardiovascular risks. Anatomical contributors such as tonsillar hypertrophy, nasal obstruction, turbinate hypertrophy, and tongue-base encroachment play key roles in OSA pathogenesis [1]. Nasal obstruction increases inspiratory resistance, predisposing to downstream pharyngeal collapse via the Starling resistor mechanism [2].
Despite this, commonly used OSA staging systems, such as Friedman’s, focus on tonsils, tongue position, and BMI but do not explicitly include nasal obstruction [3]. Yet nasal pathology can significantly affect sleep breathing and reduce CPAP tolerance [4,5]. There is a need for a unified anatomical scoring system to guide decision-making in ENT sleep clinics. We propose ACUOS: a 0–16 score incorporating five anatomical variables and optional modification for pediatric adenoid hypertrophy.
METHODS
Five components were selected based on published
anatomical predictors of OSA:
• Tonsil size (Brodsky scale): 0–4
• Septal deviation (% airway obstruction): 0–3
• Inferior turbinate hypertrophy: 0–3
• Tongue position (Modified Mallampati): 0–3
• Body Mass Index (kg/m²): 0–3
The total score (0–16) stratifies patients into four stages with guidance on likely management options. In pediatric cases, adenoid obstruction (0–3) may be added as a modifier [6,7].
ACUOS is designed for outpatient evaluation using anterior rhinoscopy or nasal endoscopy, BMI measurement, and modified Mallampati scoring.
Table 1. ACUOS Scoring Components and Point Values
|
Component |
Description |
|
Points |
|
Tonsil size (Brodsky) |
0: absent → 4: >75% or kissing tonsils |
|
0–4 |
|
Septal obstruction |
<25% → >75% (endoscopy/CT) |
|
0–3 |
|
Inferior turbinate hypertrophy |
<25% → >75% airway filling |
|
0–3 |
|
Tongue position (Mallampati) |
Class I → IV |
|
0–3 |
|
BMI (kg/m²) |
<25 → ≥35 |
|
0–3 |
Figure 1. ACUOS Staging and Suggested Management Pathway
• Stage A (0–4): Medical therapy, nasal steroid/irrigation, allergy control
• Stage B (5–8): Tonsillectomy if tonsils ≥3; correct nasal obstruction
• Stage C (9–12): DISE to assess multilevel obstruction → combined surgery or CPAP
• Stage D (13–16): CPAP first; consider staged surgical correction, especially if BMI ≥35
Figure 1. ACUOS Staging and Suggested Management Pathway
RESULTS
Table 2. Example scoring using ACUOS:
| Component | Score |
| Tonsil Grade 3 | 3 |
| Septal Deviation (50–75% Obstruction) | 2 |
| Inferior Turbinate Hypertrophy (50-70%) | 2 |
| Mallampati II | 1 |
| BMI 31 kg/m² | 2 |
| Total Score | 10 → Stage C |
Interpretation: Stage C (9–12): Multilevel airway obstruction → DISE advised; consider combined palate, tonsil, nasal, ± tongue base surgery or trial of CPAP.
Rationale and Literature Basis
DISCUSSION
ACUOS incorporates both nasal and oropharyngeal factors overlooked in standalone staging systems and can facilitate:
• Quick outpatient surgical counseling
• Consistent anatomical reporting in clinical trials
• Stratification of patients for targeted nasal/tonsillar or multilevel OSA surgery [8]
However, this proposal remains theoretical and requires cross-sectional validation and inter-observer reliability evaluation [9]. Additionally, ACUOS does not attempt to predict physiological contributors like loop gain or arousal threshold [10] and should therefore complement PSG rather than replace it.
Future work should include prospective cohort studies applying ACUOS at baseline, correlating it with surgical and non-surgical treatment outcomes, and refining cut-offs and weightings. Validation in different populations and in children (with adenoid modifier) is also needed. In the Bangladeshi/Indian context, where resource constraints may limit full DISE or imaging, ACUOS offers a practical, bedside tool using endoscopic and clinical assessment.
CONCLUSION
Arefin’s Combined Upper Airway Obstruction Score (ACUOS) provides a single, clinically simple tool to measure anatomical burden in OSA and guide ENT-led treatment pathways. Early adoption may help standardize reporting and decisionmaking, with validation studies needed to support wider use.
ACKNOWLEDGEMENTS
None.
CONFLICT OF INTEREST
The author has no conflict of interest.
REFERENCES